BERWYN, Pa.–(BUSINESS WIRE)– #pharma–Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has received a ruling on the lawsuit filed by Scilex Pharmaceuticals (NASDAQ:SCLX) and Sorrento Therapeutics, the now bankrupt majority owner of Scilex Pharmaceuticals. The Court found in